Home » Topics » Disease categories and therapies » Endocrine/metabolic

Endocrine/metabolic
RSS

FA-70D: a new cathepsin inhibitor from Taiho

Dec. 17, 1997

Vitamin D analogue undergoes phase I evaluation for osteoporosis

Dec. 17, 1997

rhIL-11 reduces need for platelet transfusion in breast cancer patients on high-dose chemotherapy

Dec. 16, 1997

FDA approves new alternative to hysterectomy in women with menorrhagia

Dec. 16, 1997

Searle describes selective alphav/beta3 integrin antagonists

Dec. 16, 1997

Alteon and Genentech collaborate on diabetic complications therapy

Dec. 15, 1997

Effects of F-1394 on cholesterol esterification/secretion in cultured human intestinal cells

Dec. 15, 1997

Raloxifene clinical data supports therapeutic utility of novel SERM

Dec. 15, 1997

Cangene to evaluate Leucotropin in phase III

Dec. 15, 1997

Discovery of novel, orally active ACAT inhibitor, FR-186054, reported by Fujisawa

Dec. 15, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
Maintenance, man: Lilly’s phase III weight trial hits goals
BioWorld
Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...
AI drug developer Insilico to raise $292 million in Hong Kong IPO
BioWorld
Insilico Medicine Inc. plans to raise HK$2.27 billion (US$292 million) in its IPO on the Hong Kong Securities Exchange to advance its clinical pipeline and invest...